-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Universal Cancer Peptide-Based Vaccine (UCPVax) is a therapeutic cancer vaccine consisting of two highly selective helper peptides that induce CD4+ T helper cell 1 responses
According to the Bayesian-based design of phase IB and IIa phases, patients with refractory NSCLC are assigned to receive three doses of the UCPVax vaccine (0.
A total of 59 patients received UCPVax treatment; 95% of patients have undergone third-line system therapy
Disease control was achieved in 21 (39%) patients (disease stable, n=20; complete remission, n=1
Taken together, the findings suggest that UCPVax is highly immunogenic and safe, and can provide a considerable one-year overall survival rate
Original source:
Olivier Adotévi, et al.